Ecolab Inc. (NYSE: ECL) — A Pristine Water-and-Hygiene Compounder Paying a Full Price to Buy Its Way Into AI Cooling

Report date: 2026-06-19 | Independent fundamental research

Subject company: Ecolab Inc., Saint Paul, Minnesota. NYSE: ECL. CIK 0000031462. FY-end December 31. ~$16.1B FY2025 revenue; ~48,000 associates; customers in 170+ countries.

⚡ Author’s Take

This block is the author’s own independent opinion and general information — not investment advice. The analysis that follows (sections 1–15) is written to take no position and names no price target outside this block.

Verdict: HOLD / accumulate-on-weakness. A genuine quality compounder at a full — but not euphoric — price. Not a BUY here (the easy margin-recovery EPS growth is largely spent and the AI-cooling option was bought rich); not an AVOID (the moat is real, pricing power is proven, the multiple is only mid-percentile by ECL’s own lofty history). Accumulate into weakness toward ~$220–250 (≈26–30x adj. EPS / ~17–18x EV/EBITDA), where the stock re-rates toward the VLTO/Xylem water-peer band and the CoolIT AI-cooling call option comes closer to free. Medium conviction.

Ecolab is one of the highest-quality businesses in the specialty-chemicals universe: a razor/razorblade, service-led franchise that sells mission-critical-but-cheap chemistry through installed dispensing equipment and the industry’s largest field force, locking customers in via switching costs, food-safety/regulatory validation, and an agency dynamic (the quality manager who specifies Ecolab does not pay the bill but owns the career risk of a failure). The proof the moat is real is in the income statement: ECL absorbed a ~700bp gross-margin shock in 2021–22 (gross margin fell to 37.8%) and pushed multi-year value pricing to fully recover it to 44.5% by 2025 — without losing volume. That is demonstrated pricing power, the financial signature of customer captivity. The problem for the buyer at $269 is twofold. First, that EPS doubling (2022→2025) was overwhelmingly a one-time margin recovery, not units — gross margin is now back near its prior peak, so the next leg must come from a harder mix of ~1–2% volume + price + acquisitions, beneath a ~36x multiple that prices a structurally faster grower. Second, management has bolted a $4.75B, 29x-NTM-EBITDA bet on AI direct-to-chip liquid cooling (CoolIT) onto the balance sheet — debt-funded (pro-forma leverage ~2x→~3x), at the apex of the AI-data-center narrative, in a fast-iterating hardware arena that is the opposite of ECL’s chemistry annuity. That is a textbook Marathon “capital floods to the hot pool” signal, and it sits on top of a long history of buying scale at full prices (Nalco, Purolite, Ovivo) that has kept consolidated ROIC at only ~13% for a wide-moat name.

The framing is “quality-compounder-at-a-price,” not falling knife and not bubble. The factor read confirms it: beta 0.59, idiosyncratic vol just 15.1%, loadings on LowVolatility (+0.23) and Quality (+0.12), negative on Growth (−0.16) — the market still treats ECL as a defensive Dividend Aristocrat, not an AI-beta name. That defensive bid is exactly what underwrites the premium and what caps the upside: the asymmetry mirrors the LIN/SHW setup — limited upside if everything goes right, real downside on multiple de-rate alone (the stock fell 43% peak-to-trough in 2022 and has compounded only ~5.9%/yr over five years through that round-trip). Conviction: medium. Flips bullish if organic volume sustains mid-single-digit AND CoolIT/High-Tech/bioprocessing visibly re-rate group organic growth toward ~6%+ with margins held (proving the algorithm is structural, not a recovery artifact). Flips bearish if volume stalls near 1%, the gross margin rolls back as raw-material deflation reverses, or CoolIT’s economics disappoint into rising leverage. Tag: clean business, full price, and a $4.75B AI-cooling bet bought at the top of the tank.

📈 Stock Price Action — Five-Year Event Map

Over five years ECL has round-tripped through a brutal margin-driven bear market and back to new highs: from ~$200 (early 2021) to a ~$126 trough (Nov 2022) as input-cost inflation crushed margins, then a steady ~2.4x recovery to a $307.60 all-time high (Feb 2026) as pricing restored margins — before fading ~12% to $269.12 (2026-06-18) on the CoolIT-funding debt overhang and a fully-valued multiple. 52-week range $242.49–$307.60; the stock sits ~12% off its high, roughly in the middle of its one-year range, above its 200-day EMA (~$265).

Cycle narrative. (1) 2021 was a reopening year — institutional/foodservice volumes normalized and ECL announced the $3.7B Purolite (bioprocessing resins) deal. (2) The 2022 collapse was not a demand failure but a margin failure: surfactant, caustic, resin and energy costs spiked ~50%, gross margin fell ~700bp to 37.8%, and a long-duration quality compounder de-rated hard as rates rose. (3)–(5) The entire 2022→2026 recovery is a pricing-over-deflating-input margin story: ECL pushed multi-year value pricing, input costs eased, gross margin climbed back to 44.5% and adjusted EPS roughly doubled — re-rating the stock to new highs. (6) The AI-cooling/data-center narrative (Ovivo ultrapure water close, High-Tech +20%+) added a growth-optionality layer that carried it to the Feb-2026 ATH. (7) The recent ~12% pullback coincides with the March-2026 CoolIT announcement and the May-2026 $5.0B senior-notes issuance to fund it — the market digesting a richly-priced, debt-funded AI-hardware acquisition on top of an already-full multiple. (Price moves are Fact, from the AZI 5-yr CSV; attributed drivers are Interpretation, cross-referenced to 8-K/earnings dates and the news feed.)

1. Executive Summary

Ecolab is the global #1 in water treatment chemistry and in institutional/foodservice hygiene and infection prevention — a ~$16.1B-revenue, four-segment franchise (Global Water $7.68B; Global Institutional & Specialty $5.96B; Global Pest Elimination $1.22B; Global Life Sciences $0.71B, FY2025) built on a service-led, razor/razorblade model: low-cost-per-unit but mission-critical consumable chemistry, dispensed through ECL-installed equipment and supported by the largest direct field sales-and-service force in the industry (~48,000 associates). Demand is highly recurring (consumption + embedded equipment + the service relationship), though revenue is technically 78% product/equipment, 22% service/lease — a softer recurrence than Linde’s contracted take-or-pay annuity, but far stickier than a one-shot product sale.

The moat is genuine and proven, but narrower than the marketing. It is principally customer captivity / switching costs (installed dispensers, regulatory/food-safety validation, EcoSure audits, mission-critical-but-tiny-cost chemistry → price-inelastic, switch-averse buyers) plus economies of scale in the route/service network and applied R&D (~$370M/yr). The financial proof is the full recovery of a ~700bp gross-margin shock through multi-year value pricing without volume loss. But the moat is segment-specific — widest in Institutional & Specialty (22.8% margin, ~46% of segment operating income) and Pest Elimination (asset-light routes), thinnest in commoditized industrial Water (16.5%) and contested Life Sciences (17.1%) — and consolidated ROIC is only ~13%, dragged down by a ~$12.9B goodwill+intangible load from decades of premium-priced M&A. Incremental/organic returns in the service lines are much higher than the consolidated GAAP figure implies, but shareholders capture mid-teens, not high-20s, on the consolidated base because management has consistently paid for its scale.

The investment tension is between business quality and price. ECL trades at ~36x trailing P/E, ~21x EV/EBITDA, ~5.1x EV/sales and ~1.3% yield — the top of the quality-industrial/water complex, a premium even to higher-ROIC Linde (24% ROIC) and well above the directly comparable Veralto/Xylem/IDEX water peers (16–17x EBITDA). On its own history the multiple is full but not extreme (composite 66th percentile; P/E 55th) — ECL has structurally traded 30–40x for two decades. The 2022→2025 EPS doubling was a one-time margin recovery now largely lapped, so forward growth must come from ~mid-single-digit organic (currently ~4%, of which ~1% volume), continued price, mix shift toward 20%+ growth engines (data-center cooling/High-Tech, bioprocessing, Digital), and the CoolIT acquisition — a $4.75B, 29x-NTM-EBITDA, debt-funded bet on AI direct-to-chip liquid cooling that lifts pro-forma leverage to ~3x and is the central capital-allocation question. Capital allocation is otherwise exemplary on dividends (34-consecutive-year Dividend Aristocrat, ~36% payout) but mediocre on buybacks (modest, peak-priced, dilution-offsetting). Incentives are above-average (an explicit organic-ROIC LTIP gate) with one blind spot: the comp ROIC metric excludes purchase accounting, so a 29x-EBITDA deal does not penalize management. Insiders are net mildly bullish (a ~$2M director open-market buy in June 2026; recurring lead-director accumulation), with the large $ of selling attributable to Cascade/Gates (still 12.2% holder) diversifying. Embedded expectations require the 12–15% adjusted-EPS algorithm to prove durable for years AND the AI-cooling optionality to be real; the market is pricing that as likely, and the dominant risk is a multiple de-rate alone. (No recommendation or price target in this body; see the Author’s Take above for the labeled subjective view.)

2. Business Overview

What Ecolab does. Founded 1923 (as Economics Laboratory), Ecolab is the world’s leading provider of water, hygiene, and infection-prevention solutions and services. It sells proprietary chemistry — detergents, sanitizers, water-treatment chemicals, antimicrobials, lubricants, ion-exchange resins — and the systems and service that deliver it: digitally-enabled dispensers and injectors, leased high-efficiency dishmachines, 3D TRASAR water controllers and monitoring, and a field force of tens of thousands of sales-and-service associates who become embedded in customers’ daily operations. Its mantra, “circle the customer — circle the globe,” is now institutionalized as the One Ecolab enterprise selling model: a single customer (a global hotel chain, a food processor, a hospital system) buys warewashing, laundry, pest, water and food-safety programs across multiple segments, and ECL follows that customer across all its sites worldwide. (FACT: FY2025 10-K Item 1.)

Segment structure (re-segmented Q1 2025). Effective Q1 2025, Ecolab moved from its legacy three-segment structure to four reportable segments. The memo uses the current structure throughout. FY2025 operating-segment economics (10-K segment note):

Profit-pool concentration. Institutional & Specialty contributes ~46% of segment operating income on ~38% of sales; Global Water ~42% of OI on ~49% of sales. The hygiene/institutional franchise — not water — is the margin engine. “Global High-Tech” (data centers + microelectronics) is not a reportable segment; it is a cross-cutting growth engine housed inside the Light & Heavy operating segment within Global Water. (FACT: 10-K segment note.)

How it makes money. The razor/razorblade economics: ECL often places the dispensing equipment at low or no upfront cost and earns recurring margin on the consumable chemistry used through it. Warewashing products alone were 13% of consolidated sales in 2025 (the single largest product concentration). The model is geographically and end-market diversified — customers across 40+ industries in 170+ countries, no single customer or distributor >10% of revenue. Revenue mix by type: product & equipment $12,618.5M (78%); service & lease $3,462.7M (22%). The recurrence is real but flows from consumption (sanitizer and water chemistry are used up daily and re-ordered) plus embedded equipment and the service-rep relationship — not from long-term take-or-pay contracts. (FACT: 10-K revenue disaggregation; “Customers and Classes of Products.”)

Verdict. A diversified, recurring-consumption, service-led specialty franchise with a sensible enterprise selling model and no meaningful customer concentration — a structurally attractive business model whose quality is concentrated in the hygiene/institutional and pest franchises and diluted by the larger, more commoditized industrial-water book.

3. Industry Dynamics

Structure and size. Ecolab’s company-cited serviceable addressable market for water, hygiene and infection prevention exceeds $150B (~$152B), of which ECL’s ~$16B is ~10% penetrated — a long runway in a fragmented field that ECL can keep consolidating. The global industrial water-treatment market is ~$46B (2024), growing to ~$72–81B by 2033–35 at ~5% CAGR; in water-treatment chemicals, Ecolab (#1), Solenis (~20%) and Kemira together hold >30% of global revenue — consolidated at the top, fragmented in the tail. (FACT: ECL IR; Grand View Research / GlobeNewswire 2025; MarketsandMarkets / Chemical Week 2025.)

Secular demand drivers — all structural tailwinds. (1) Water scarcity — ECL’s value proposition is “do more with less water and energy”; it helped customers conserve 226B gallons in 2024 (targeting 300B by 2030), and rising water cost makes its efficiency programs ROI-positive for customers. (2) Food safety — ECL protects roughly one-third of the world’s food production; regulation and third-party auditing keep rising. (3) Antimicrobial resistance / infection prevention — hospital-acquired-infection economics. (4) AI data-center water + direct-to-chip liquid cooling — the new high-growth vector (CoolIT/Ovivo): management frames the Global High-Tech opportunity as roughly doubling from ~$5B to ~$10B with CoolIT, growing “strong double digits,” with ECL already serving >1,000 data centers. (5) Microelectronics ultrapure water (Ovivo Electronics, semiconductor fabs). (FACT: 10-K Item 1; CoolIT/Ovivo 8-Ks.)

Marathon capital-cycle read — the important nuance. For the core legacy water/hygiene business the supply side is favorable and stable: the industry is consolidated, there is no greenfield-capacity frenzy, and high returns have not drawn destructive new supply because the moat is a service network, not a buildable asset. But the two hot growth pools flash caution. (a) Data-center liquid cooling is attracting a flood of capital — Vertiv, Schneider Electric (Motivair), Boyd, nVent, Asetek, Delta, plus chipmakers’ own reference designs — and ECL paid ~$4.75B (≈8.6x sales) for CoolIT at the apex of the AI-cooling narrative. This is precisely the Marathon “high returns attract capital, mean-revert” zone, and direct-to-chip CDU/cold-plate hardware is a fast-iterating, lower-moat hardware business unlike ECL’s chemistry annuity. (b) Solenis (Platinum Equity, post-Diversey, >$8B combined revenue) and Veolia (took full ownership of Water Technologies & Solutions in May 2025) are both consolidating and pushing into Ecolab’s highest-margin institutional/foodservice hygiene pool. (INTERPRETATION; FACT on the transactions.)

Verdict: structurally good-to-very-good core, with a hot-but-contested growth overlay. The legacy business is consolidated, secularly growing ~GDP+, regulation-favored, and protected by service barriers — a better structure than RPM’s fragmented coatings tail or SHW’s cyclical-housing exposure, though not as good as Linde’s contract-locked regional gas monopolies. The new growth pools (data-center cooling, electronics water) are genuinely fast-growing but contested and capital-attracting, where returns are far less certain.

4. Competitive Position

Name the moat (Greenwald). Ecolab’s competitive advantage is a combination of (1) customer captivity / switching costs — the dominant, genuine source; (2) economies of scale in the direct sales-and-service network, route density and applied R&D; and (3) modest intangibles (brand, regulatory validation: Nalco, Kay, EcoSure, Anios, Microtek). It is not a low-cost-input or patent moat — inputs are commodity chemistry and ECL is largely a price-taker on raw materials (commodity cost +9% in Q1’26).

The switching-cost core. Once ECL’s dispensing/monitoring equipment is installed, the service rep is trained into the customer’s daily operation, and the chemistry is validated into the customer’s food-safety/regulatory/audit regime (HACCP, FDA, hospital infection-control protocols, EcoSure brand-standard audits), the cost of switching is high relative to the small dollar value of the chemical itself. The chemical is a tiny share of the customer’s cost base but a catastrophic failure point (a foodborne-illness outbreak, a hospital infection, a Legionella event, a boiler failure) — so customers are price-inelastic and switch-averse. An agency dynamic reinforces it: the quality/plant manager who specifies Ecolab is not the one paying and bears the career risk of a switch. (INTERPRETATION, grounded in 10-K model description.)

The financial proof the moat is real. ECL pushed multi-year value pricing that drove the gross-margin round-trip from 37.8% (2022 trough) back to 44.5% (2025) and operating margin from 12.0% to ~18% without losing volume — Q4’25 organic +3% (price + positive volume), Q1’26 organic +4% (price +3%, volume +1%), FY26 guide +2–3% value pricing on top. A price-taker on inputs that can nonetheless realize multi-year positive price and fully recover a ~700bp gross-margin hit displays demonstrated pricing power — the financial signature of customer captivity. The market-share-stability test passes (qualified): ECL is #1 globally in water-treatment chemicals and in institutional hygiene/infection prevention, holding share for decades — but in fragmented markets with credible scaled challengers (Solenis ~20% of water chemicals), so this is durable share leadership, not Linde-style regional monopoly.

Competitive map by arena.

• Water treatment ($7.7B): #1 globally (Nalco Water). Rivals: Solenis (private; ~20% share; cost-competitive, post-Diversey now also in hygiene), Veolia WTS (engineering + chemicals, strong municipal/large-industrial), Kurita (APAC, membranes), Kemira (pulp/paper). ECL wins on integrated chemistry + digital (3D TRASAR) + global service + sustainability/ROI selling; loses where buyers want lowest-cost commodity chemistry or pure equipment.
• Institutional & Specialty ($6.0B — the crown jewel, 22.8% margin): #1 globally. The key competitive development is Solenis/Diversey — the 2023 Diversey merger put a scaled #2 into ECL’s highest-margin pool. ECL’s switching-cost moat is strongest here (installed dishmachines, leased equipment, EcoSure audits, chain corporate-account lock-in); Diversey under Platinum/Solenis is the share-gain threat to watch.
• Pest Elimination ($1.2B, 19.4% margin, asset-light, +7%/yr): competes with Rentokil (Terminix), Rollins (Orkin), Anticimex; ECL’s niche is commercial/food-safety-integrated pest bundled into the One Ecolab sell — a defensible, high-return route business.
• Life Sciences ($0.7B, 17.1%, lumpy): pharma/biotech cleaning + Purolite bioprocessing resins; competes vs STERIS/Contec (cleanroom) and Cytiva/Thermo/Repligen/Merck (resins). Sub-scale, contested — the weakest moat segment.
• Data-center cooling (Global High-Tech, emerging): pre-CoolIT, cooling-water chemistry + Ovivo ultrapure water; post-CoolIT adds direct-to-chip CDUs/cold plates against Vertiv, Schneider, nVent, Boyd, Asetek — hardware, lower moat, fast iteration, the opposite of ECL’s chemistry annuity.

The key tension — wide-moat narrative at ~13% ROIC. ROIC ~13.1% (FY25) and ROE 16.5% are mid-teens — decent, but not the 20–30% of a truly wide-moat compounder (Linde ~24%; Zoetis ~24%; IDEXX higher; SHW ~16–17%). The moat is real (pricing power + share durability prove it) but consolidated return is dragged by (a) a ~$12.9B goodwill+intangible balance from decades of M&A — ECL paid for much of its scale, so purchase-accounting capital depresses ROIC even where the underlying franchise earns high returns on tangible/incremental capital; and (b) the capital-intensive, lower-return industrial-water + electronics-water build. The asset-light service lines (Pest, Institutional) earn well above 13%. Net verdict: a durable but narrower-than-marketed, segment-specific moat — widest in Institutional and Pest, thinnest in commoditized Water and contested Life Sciences — that translates into mid-teens consolidated returns because management bought its scale at full prices.

5. Growth History and Forward Opportunities

Revenue history. $12.73B (2021) → $14.19B (2022) → $15.32B (2023) → $15.74B (2024) → $16.08B (2025) — a ~6% reported CAGR off the 2021 base, blending price-led recovery, mix and bolt-on M&A. FY2025 headline net sales rose +2.2% (Water +2.7%, I&S +0.0% (depressed by the 2024 surgical divestiture in the base + FX), Pest +7.2%, Life Sciences +6.9%); underlying organic was higher. Q4’25 organic +3% (price + positive volume); Q1’26 organic +4% (price +3%, volume +1%); FY26 guide organic +3–4% accelerating. (FACT: 10-K MD&A; Q1’26 call.)

The earnings surge was a margin recovery, not a volume boom. The 2022→2025 EPS doubling (diluted cont-ops $3.87 → $7.34; adjusted ~$5+ → ~$7.53; adj. EPS +12–15%/yr) was driven overwhelmingly by margin recovery — gross margin 37.8% → 44.5%, operating margin 12% → ~18% — i.e., pricing over deflating inputs plus the One Ecolab cost program. Segment proof: Institutional & Specialty OI rose $856.5M (2023) → $1,202.2M (2024) → $1,357.8M (2025) even as segment cost of sales fell — textbook margin recovery. This is the same pattern flagged in the SHW and RPM reports: a recovery cycle now largely complete, with gross margin back near its prior peak. Future EPS growth must lean more on volume and new engines than on further margin round-trip. (FACT / INTERPRETATION.)

Organic vs acquired. ECL is a structural serial acquirer: FY25 acquisition cash outflow $1.64B (Ovivo Electronics, semiconductor ultrapure water, closed Dec 16, 2025); pending CoolIT ~$4.75B (expected ~3Q26 close, ~$550M sales, adding ~2% to Water organic / ~1% to total once integrated); history includes Nalco (2011, ~$8B), Purolite (2021, ~$3.7B, bioprocessing resins). Inorganic growth is part of the algorithm — and the ~$12.9B goodwill+intangible load is its cost and the consolidated-ROIC drag.

The new high-quality growth engines. Global High-Tech/data centers (+20%+ in Q1’26), Life Sciences/bioprocessing (+11% Q1’26, bioprocessing volume “doubled”), and Digital (+20%+). These are genuinely faster-growing and — ex the CoolIT hardware piece — reasonably high-margin and recurring. Management’s long-term algorithm targets ~mid-single-digit organic sales and ~13–15% adjusted EPS growth.

Verdict: mixed-to-good growth quality. Core growth (Pest, Institutional, water chemistry) is high-quality, recurring and pricing-rich. The past three years’ EPS growth was lower-quality in that it was a one-time margin recovery, not units. The marquee forward bet (data-center cooling) is bought inorganically at a narrative-peak price and skews toward lower-moat hardware. The swing factor is organic volume: the +1% in Q1’26 turning to sustained mid-single-digit would re-rate growth quality up; a stall that leaves EPS leaning on price + acquisitions would re-rate it down.

6. Financial Quality

Margins and operating leverage. Gross margin 37.8% (2022) → 40.2% → 43.5% → 44.5% (2025) — near the pre-COVID peak. Operating margin 12.0% → ~18.0%; EBITDA margin 18.6% → 24.1%; net margin 7.7% → 12.9%. Incremental operating margin was ~82% in 2025 and ~121% in 2024 — strong drop-through on the recovery, which by definition is not repeatable once margins normalize. (FACT: ROIC profitability ratios reconciled to 10-K.)

Returns on capital. ROIC 8.5% (2022 trough) → 13.1% (2025); ROE 11.6% → 16.5%; ROA 5.1% → 8.8%. The decade-long context matters: ROIC sat ~10–11% through the 2016–2019 post-Nalco/Champion digestion (barely above WACC), troughed in 2022, and recovered on margins — not on superior incremental returns. Mid-teens ROIC on a ~$30B invested-capital base carrying ~$12.9B of goodwill+intangibles is the financial signature of a real franchise bought at full prices. (FACT.)

Cash generation and conversion. FY25 operating cash flow $2.95B; capex ~$1.1B; free cash flow ~$1.83B (~11% FCF margin). OCF/NI ~1.42x — clean conversion, aided by D&A ($976M) exceeding capex. SBC is small (~$137M, ~0.8% of sales) — a genuine cost but not an earnings-quality red flag. Capex intensity ~7% of sales is moderate and rising with the electronics-water/Ovivo build. (FACT: ROIC cash-flow statement; note ROIC’s “free_cash_flow” field equals OCF — capex sits in investing.)

Balance sheet (pre-CoolIT). FY25 cash $646M; total debt ~$9.0B; net debt ~$7.59B; net debt/EBITDA ~1.96x — investment-grade and comfortable. Goodwill $9.23B + other intangibles $3.69B = $12.9B (52% of total assets) — heavily acquisitive; tangible common equity is negative (goodwill exceeds equity), typical for a serial acquirer. Pro-forma for CoolIT (~$4.75B funded substantially by the May-2026 $5.0B senior-notes issuance), net leverage rises toward ~3x — a material step-up in financial risk taken to fund an AI-narrative-priced deal, and a key item to watch for rating-agency action and buyback suspension. (FACT: 10-K balance sheet; 8-Ks 2026-04-15, 2026-05-29.)

Quality-of-earnings / one-time items. Use adjusted EPS for run-rate. GAAP is noisy: 2020 carried a ChampionX (energy) separation loss that produced a GAAP net loss (~−$1.2B) while operating ROIC held ~9% — a discontinued-ops artifact, not operating deterioration. 2024 GAAP EPS was inflated ~$0.90 by a $355.9M ($257.7M after-tax) gain on the Global Surgical Solutions divestiture — which is why GAAP EPS fell $7.44 (2024) → $7.34 (2025) even as underlying adjusted EPS grew ~12–13%. 2025 carried $150.3M of special charges (One Ecolab restructuring). The 2021–22 gross-margin trough and Nalco/Purolite intangible amortization are cyclical/structural drags now substantially recovered. (FACT: 10-K Notes 3 & 4.)

Verdict: high financial quality, with the caveat that the recent growth rate is partly cyclical. Economics genuinely improve with scale in the service segments; margins, conversion and balance-sheet discipline are strong. But the headline EPS growth of the last three years was a one-time margin recovery, the consolidated ROIC is only mid-teens, and the balance sheet is about to lever up to ~3x to fund a richly-priced acquisition — so “high quality” should not be read as “structurally high-growth” or “high-return on the consolidated base.”

7. Capital Allocation

M&A — competent builder, full-price buyer (Marathon caution). The franchise-building deals worked strategically but diluted ROIC for years: Nalco (2011, ~$8B) was transformational but kept ROIC ~10–11% for a decade; Champion Technologies (2013, energy) was eventually exited via the ChampionX spin (2020) — a costly round-trip; Purolite (2021, ~$3.7B bioprocessing resins) is high-quality but premium-priced. The 2025–26 pivot is the aggressive chapter: Ovivo (Dec 2025, $1,595.7M; 69% goodwill, negative tangible book) and especially CoolIT — announced March 20, 2026, ~$4.75B cash from KKR at an explicit 29x NTM / 24x 2027 adjusted EBITDA (~8.6x sales on ~$550M), the most aggressive deal in ECL’s recent history, in fast-iterating AI-cooling hardware, debt-funded ($4.75B delayed-draw term loan, termed out by a $5.0B senior-notes issuance in May 2026). The recurring pattern: large, premium-multiple, goodwill-heavy deals earned back slowly. Whether CoolIT earns ECL’s ~15.9% organic-ROIC hurdle is the central capital-allocation open question, with goodwill-impairment risk if the AI-cooling capex cycle rolls over. A genuine offsetting positive: management does prune — Global Surgical Solutions (2024) and the ChampionX energy separation (2020) show real portfolio discipline. (FACT: 10-K Note 4; 8-Ks 2026-03-20, 04-15, 05-29.)

Capital return — exemplary dividend, mediocre buyback. ECL is a verified Dividend Aristocrat: a December-2025 increase of 12% to $0.73/quarter marked its 34th consecutive annual increase (and 89 consecutive years of paying — not yet a King, which needs 50 years of increases). Dividends paid $617M → $664M → $754M (2023–25), ~36% payout, ~41% of FCF — well-covered, double-digit growth, ~1.3% yield (a dividend-growth, not dividend-yield, story). Buybacks, by contrast, were $14M (2023, essentially paused), $987M (2024), $784M (2025) — executed near all-time-high ~36x P/E while the 2023 low went un-bought, and largely offsetting SBC/vesting (diluted shares fell only ~2.5% over 2019–25 despite >$1.8B of 2024–25 repurchases). Combined FY25 return (~$1.54B) was ~84% of FCF, leaving little room to de-lever — hence the debt-funded CoolIT deal. Net: best-in-class on dividends, unremarkable buyback efficiency. (FACT: 10-K Items 5 & 7.)

Incentives and governance — above-average, one blind spot. CEO Christophe Beck’s FY25 total comp was $17.4M (vs $16.4M FY24); pay ratio 326x; say-on-pay ~90%. The annual MIP keys on adjusted diluted EPS (FY25 actual $7.53 vs $6.85 threshold → 137% payout) plus organic sales, operating margin and FCF. The long-term PBRSU keys on organic return on invested capital with a hard gate (no payout below threshold) and a relative-TSR modifier (2026–28 organic-ROIC target 15.9%) — a genuinely good, capital-discipline-aligned design that is rare. The blind spot: comp ROIC “excludes the purchase-accounting impact,” so an expensive deal like CoolIT does not penalize the LTIP — weakening the restraint on rich M&A. Beck added the President title in April 2026 (Chairman/CEO/President in one person; Lead Independent Director David MacLennan is the governance offset). No founding family; the largest holder is Cascade Investment / Gates Foundation Trust at 12.18%, with Gates’s CIO Michael Larson a director since 2012 — a stable, sophisticated, patient anchor (Vanguard 8.21%, BlackRock 7.69%). (FACT: DEF 14A 2026-03-20.)

Insider transactions — net mildly bullish. Across 284 Form 4s (Jan-2024 → Jun-2026), routine grants/vesting/tax dominate (codes A/M/F), with 10 genuine open-market buys (code P) — notably director Michel Doukeris (AB InBev CEO) buying ~7,750 shares ≈ $2.0M at ~$258 on 2026-06-11, an officer buy by EVP Benjamin Clark (~$264K), and Lead Director MacLennan’s recurring quarterly accumulation. The ~$535M of sales is overwhelmingly Cascade/Gates programmatic 10b5-1 diversification (still a 12.18% holder) — an outside-anchor rebalancing, not a management top-call. No red-flag insider distribution. (FACT: Form 4 corpus.)

Verdict: a competent, shareholder-respecting capital returner but a full-price acquirer. The dividend is exemplary; the buyback is mediocre; incentives are above-average; and the debt-funded, 29x-EBITDA, narrative-peak CoolIT bet into a lower-moat hardware pool is the central capital-allocation risk and the swing factor for forward ROIC and leverage.

8. Changes and Headwinds — Last Two Years

• The CoolIT acquisition + ~$5B debt (2026) — the dominant event: a $4.75B, 29x-NTM-EBITDA AI-direct-to-chip-cooling acquisition announced March 2026, funded by a $4.75B delayed-draw term loan and a $5.0B senior-notes issuance (May 2026), lifting pro-forma leverage toward ~3x. Weakens the thesis on price/leverage; strengthens it on growth optionality. (FACT.)
• Ovivo Electronics close (Dec 2025) — $1.6B, semiconductor ultrapure water; expands the electronics-water/High-Tech vector; 69% goodwill.
• Q1 2025 re-segmentation — to four segments (Global Water / Institutional & Specialty / Pest / Life Sciences); Life Sciences elevated, Healthcare dissolved into Institutional after the 2024 surgical divestiture.
• Margin recovery completion — gross margin restored to 44.5% (near prior peak); the EPS-doubling tailwind is largely lapped.
• High-growth engines inflecting — High-Tech/data centers, bioprocessing and Digital each +20%+ (bioprocessing volume “doubled” in Q1’26).
• Board refresh — Doukeris (Feb 2025) and Whalen (Aug 2025) added as directors; Reich not standing for re-election (May 2026); clean internal supply-chain succession (Duijser departure 2025).
• Commodity inflation re-emergence (2026) — commodity cost +9% in Q1’26; management expects to fully offset within “a few quarters” via pricing (vs the +50% shock of 2022). A test, not yet a problem.
• Competitive intensification — Solenis/Diversey (post-merger) contesting the Institutional crown jewel; Veolia consolidating water.

Verdict: net mixed. The growth-engine inflection and proven re-pricing strengthen the thesis; the debt-funded, richly-priced CoolIT bet and the completion of the margin-recovery tailwind weaken the forward setup at the current multiple.

9. Risk Analysis

Most material: a multiple de-rate (the dominant downside lever) and a CoolIT disappointment into rising leverage. The combination — a soft-volume year that triggers de-rating while CoolIT integration drags — is the realistic bear path.

10. Valuation Discussion (embedded expectations)

Where it trades. $269.12 (2026-06-18); market cap ~$75.7B; EV ~$83–84B. Multiples: P/E ~36x trailing, EV/EBITDA ~21x, EV/EBIT ~28–29x, EV/sales ~5.1x, P/FCF ~25x, P/B ~5.6x, dividend yield ~1.3%. On its own history (AZI percentiles): composite 66th, P/E 55th, P/B 65th, P/S 78th — full but not richest-ever (ECL has structurally traded 30–40x for two decades; the elevated P/S simply reflects mechanically higher price/sales as margins recovered).

What the price embeds. With a ~1.3% starting yield and ~13% consolidated ROIC, a ~25x P/FCF / ~36x P/E requires durable double-digit FCF/EPS growth for ~a decade to clear an ~8.5% cost of equity. Decomposing total return ≈ 1.3% yield + EPS growth ± multiple change: to earn ~8–9% with a flat multiple, ECL must compound EPS ~7–8%; the market is paying for more — the embedded expectation is the management 12–15% adjusted-EPS algorithm holding for years AND the AI/data-center-cooling + bioprocessing options being real, not just margin-recovery catch-up. A two-stage FCFE sanity check (justify ~$269 at ~8.5% cost of equity off ~$6.50/sh FCF) needs ~10–11% FCF growth for ten years fading to ~4–5% terminal — achievable only if the algorithm is real for 5+ years and the high-growth segments scale into the mix. Priced correctly: proven pricing power, the delivered 44.5% gross-margin recovery, Aristocrat dividend safety, low-vol quality. Potentially mis-priced: extrapolating the 2022→2025 margin-recovery EPS doubling as a repeatable run-rate when most of that catch-up is done — forward growth must come from a harder mix of ~1–2% volume + price + mix + buyback + CoolIT.

Comp set (live, TTM). ECL sits at the top of the quality-industrial/water complex on EV/EBITDA (21x) — above Linde (19.3x, but 24% ROIC), Sherwin-Williams (20.4x, ~16–17% ROIC) and Danaher (20.4x), and well above the directly comparable water peers Veralto (16.8x, the Danaher water/quality spinoff), Xylem (15.9x) and IDEX (16.3x) and Roper (15.0x). On P/E it is ~tied with Danaher at the high end (~36x) and at a premium to higher-ROIC Linde (32.7x) — hard to justify on quality alone. The sharpest tell: Veralto is cheaper on every metric at comparable margins. Pest comp Rentokil trades ~21x P/E / ~13–14x EBITDA (integration-troubled discount); Rollins is the ~40x pest premium. Net: ECL is priced as best-in-class while earning a mid-pack ~13% consolidated ROIC.

Scenario analysis (3-yr to ~FY28; base off ~$7.53 adj. FY25 EPS). (ASSUMPTION-driven; not forecasts.)

• Bear (~25%): margin recovery spent, volume ~1–2%, CoolIT drags / ~3x leverage bites; EPS growth fades to ~6–8% (FY28 adj. EPS ~$9.3–9.6); multiple de-rates toward own-history low / VLTO–XYL territory ~24–26x → ~$220–255.
• Base (~50%): organic ~4–5%, 12–13% EPS fading to ~10% (FY28 adj. EPS ~$10.7–11.0); multiple normalizes modestly to ~30–31x → ~$315–345.
• Bull (~25%): CoolIT + High-Tech + bioprocessing compound 20%+, ~15% EPS sustained (FY28 adj. EPS ~$11.5–12.0); multiple holds ~35–36x on an AI-water/cooling re-rate → ~$400–430.

The base/bull cluster ($315–430) versus bear ($220–255) is roughly symmetric-to-slightly-favorable on a multi-year hold if the algorithm holds — but the de-rate risk (multiple alone reverting from 36x toward ~26–30x) is the dominant downside lever, mirroring the LIN/SHW “limited upside if right, real downside on de-rate alone” setup. Entry point, not business quality, is the question. (No price target; ranges illustrate embedded expectations.)

11. Variant Perception

Consensus. Sell-side is predominantly Hold/Equal-weight (e.g., Wells Fargo EW, $275 PT, 2026-06-10). The consensus is “great business, full price, wait” — and the stock essentially is that consensus.

Strongest bull case. A durable low-volatility quality compounder (beta 0.59, idio vol 15.1%, 34-year Dividend Aristocrat) with proven pricing power, a structural water-scarcity/sustainability tailwind, and three 20%+ secular growth engines (data-center cooling/High-Tech, bioprocessing, Digital) now amplified by CoolIT — a rare way to own AI-capex exposure inside a defensive, recurring-revenue, switching-cost-protected franchise. The 12–15% EPS algorithm plus dividend equals double-digit compounding, and quality names like this rarely de-rate hard.

Strongest bear case. A premium 36x P/E / 21x EV/EBITDA on a business earning only ~13% consolidated ROIC and growing organic ~4% with ~1–2% volume; the 2022→2025 EPS doubling was a one-time gross-margin recovery now largely lapped; CoolIT is a debt-funded overpay (29x EBITDA) at the AI peak that lifts leverage to ~3x and adds integration/goodwill risk; the multiple prices a faster, higher-return business than the numbers support. A de-rate toward the Veralto/Xylem band (16–17x EBITDA) is the asymmetric risk.

The 3–5 assumptions that matter most, and their falsifiers.

1. The 12–15% adj-EPS algorithm is durable (not a spent recovery artifact). Falsify bull: 2–3 quarters of EPS growth slipping to high-single-digit with margin flat-to-down. Falsify bear: EPS holds 12%+ for 4+ quarters with gross margin still climbing past 45%.
2. High-growth segments scale into the mix and lift group growth/ROIC. Falsify bull: High-Tech/CoolIT growth decelerates below ~15% or proves margin-dilutive; bioprocessing “doubling” stalls. Falsify bear: these segments re-rate group organic toward ~6%+ and lift incremental margins.
3. CoolIT earns back its 29x price (>25% growth sustained, durable direct-to-chip, margins held). Falsify bull: revenue miss, hyperscaler in-housing or Vertiv/nVent competition compresses pricing, write-down. Falsify bear: CoolIT compounds >30% with held margins, ROIC-accretive by year 3.
4. The premium multiple holds (no de-rate toward 16–20x EBITDA). Falsify bull: composite percentile compresses below ~40th / EV/EBITDA toward ~17x. Falsify bear: multiple holds 21x+ through a soft-volume year.

Factor read (incorporated). Beta 0.59; LowVolatility (+0.23), Quality (+0.12) and Dividend-Aristocrat loadings; negative Growth (−0.16); factor-neighbors are AVY, PPG, SHW, the NOBL Dividend-Aristocrat ETF, water ETFs (CGW) and min-vol funds. The tape treats ECL as a defensive quality compounder, not an AI-beta name despite the CoolIT narrative — which supports the “rarely de-rates” bull framing but flags the variant: if the market starts pricing ECL as an AI-cooling growth story, the defensive bid anchoring the premium could decouple and volatility rise. The y5 return of only ~5.9%/yr (a round-trip through the 2022 trough) and the −43.7% max drawdown temper the “always compounds” bull. The variant question is whether CoolIT/AI-cooling converts ECL from a defensive low-vol compounder into a genuine secular-growth re-rate (bull) or proves a peak-cycle overpay into rising leverage (bear).

12. Fact vs. Interpretation

13. Open Questions

1. CoolIT standalone economics — margin and ROIC profile undisclosed; the earn-back math on 29x NTM EBITDA is an assumption pending segment disclosure. Does direct-to-chip hardware earn ECL-like returns, or dilute consolidated ROIC further?
2. Pro-forma post-CoolIT leverage — exact net debt/EBITDA on close (~3x?), rating-agency response, and whether the buyback is suspended to de-lever.
3. Structural vs cyclical gross margin — how much of the 44.5% is durable vs raw-material deflation that could reverse (commodity cost +9% in Q1’26)? Determines whether forward EPS growth is volume/price-driven or recovery-driven.
4. Organic volume durability — does the +1% (Q1’26) sustain toward mid-single-digit, or stall, leaving EPS leaning on price + M&A?
5. I&S share defense — does Solenis/Diversey take share in the highest-margin pool? Track I&S volume/share over the next several quarters.
6. Segment-level ROIC — undisclosed; consolidated ~13% understates the asset-light Pest/Institutional service economics and overstates the franchise’s reliance on commoditized Water.

14. What Must Be True

Bull case — what must be true:

• The 12–15% adjusted-EPS algorithm is structural, not a margin-recovery artifact — i.e., organic volume sustains mid-single-digit and gross margin holds/climbs past 45%.
• The 20%+ growth engines (data-center cooling/High-Tech, bioprocessing, Digital) scale into a large enough share of the mix to lift consolidated organic growth toward ~6% and incremental ROIC.
• CoolIT compounds >25–30% with held margins and becomes ROIC-accretive within ~3 years, validating the 29x price.
• The premium multiple (≥21x EV/EBITDA) holds because the market keeps treating ECL as a durable low-vol compounder.
• Falsification test: two-to-three consecutive quarters of EPS growth slipping to high-single-digit with margin flat-to-down, OR a CoolIT revenue/margin miss — would break the bull.

Bear case — what must be true:

• The margin-recovery tailwind is spent; forward EPS leans on ~1–2% volume + price + M&A, decelerating toward high-single-digit.
• CoolIT disappoints (hyperscaler in-housing / Vertiv-nVent competition compresses pricing) into ~3x leverage; goodwill-impairment risk.
• The 36x P/E / 21x EV/EBITDA de-rates toward the water-peer band (16–20x EBITDA / ~26–30x P/E) on any growth wobble.
• Falsification test: EPS holding 12%+ for 4+ quarters with gross margin still climbing AND CoolIT compounding >30% with held margins — would break the bear and prove the algorithm structural.

15. Source Appendix

See the Source Appendix below for the full, dated, URL-level citation list. Primary sources relied upon: Ecolab FY2025 Form 10-K (CIK 0000031462, filed 2026-02-23); 8-Ks of 2025-03-28 (segment recast), 2025-12-16 (Ovivo close), 2026-03-20 (CoolIT, ex99.1), 2026-04-15 (term loan), 2026-05-29 ($5.0B notes); DEF 14A filed 2026-03-20; Q1 2026 earnings call transcript (2026-04-28, via ROIC.ai); Form 4 corpus (284 filings, 2024–2026); ROIC.ai financial statements and ratios; AZI price history and valuation-percentile data; FactorsToday factor/leaderboard data; industry data (Grand View Research, MarketsandMarkets, Chemical Week, GlobeNewswire 2025). Management commentary is treated as a hypothesis and validated against filings and external data throughout.

APPENDIX A — Standard Diligence Questionnaire

Ecolab Inc. (NYSE: ECL) — Standard Diligence Questionnaire Appendix

Supplemental to the analysis above (report date 2026-06-19). Fact/Interpretation/Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company?

• Is the 2022→2025 EPS doubling a structural step-up or a one-time margin recovery that’s now lapped? (The central debate.)
• Does paying 29x EBITDA for CoolIT make sense, or is ECL chasing the AI narrative into a lower-moat hardware business at the peak?
• Why is consolidated ROIC only ~13% for a business marketed as wide-moat? (Answer: goodwill/intangible drag from M&A; organic ROIC is higher.)
• Can ECL sustain mid-single-digit organic volume, or is the algorithm now price-dependent?
• Is the institutional/foodservice crown jewel at risk from Solenis/Diversey?
• Is the premium multiple safe, or does ECL de-rate toward Veralto/Xylem on any wobble?

Cyclicality & Earnings Nature

• Cyclical high or low? Margins are at/near a cyclical high (gross 44.5%, near prior peak) after recovering from the 2022 trough — the easy margin tailwind is largely spent. Volume is at a cyclical low-to-normal (+1% organic). (Interpretation.)
• External environment or internal actions? Both: the 2022 margin collapse and recovery were driven by external input-cost inflation/deflation, but the pricing response (full recovery without volume loss) and the One Ecolab cost program were internal/management actions demonstrating pricing power. (Fact + Interpretation.)
• Revenue stability? High — recurring consumable demand across 40+ industries, 170+ countries, no customer >10%. Reopening-sensitive in foodservice/hospitality; otherwise stable. (Fact.)
• Market size / growth? Company-cited SAM >$150B (~10% penetrated); industrial water-treatment market ~$46B → ~$72–81B by 2033–35 (~5% CAGR); data-center cooling/High-Tech a fast-growing new vector (~$5B → ~$10B opportunity with CoolIT). Global, growing ~GDP+ with secular kickers. (Fact on figures; Interpretation on durability.)

Business Quality & Competitive Moat

• Industry more or less competitive? Core water/hygiene is consolidating (Solenis/Diversey, Veolia full WTS ownership) — modestly more competitive at the high-margin edges. Data-center cooling is highly competitive (Vertiv, nVent, Schneider, Boyd, Asetek). (Interpretation.)
• How profitable (ROIC/ROE)? ROIC ~13.1%, ROE 16.5% (FY25) — mid-teens, decent but not elite; dragged by ~$12.9B goodwill+intangibles. Organic/incremental ROIC is higher (LTIP target 15.9% organic). (Fact.)
• Industry profitability / barriers? Top-3 in water chemicals hold >30%; barriers are the service network + regulatory validation + switching costs — high in service segments, lower in commoditized chemistry. (Fact + Interpretation.)
• Easily understood? Yes — razor/razorblade consumable chemistry + dispensing + service. (Fact.)
• Undermined by foreign low-cost labor? No — value is local service density, regulatory validation and switching costs, not labor arbitrage; raw chemistry is commoditized but the delivery model is not. (Interpretation.)
• Do brands matter? Moderately — Nalco, Kay, EcoSure, Anios, Microtek carry trust/validation weight in mission-critical applications, but the moat is more switching-cost/service than consumer brand. (Interpretation.)
• Nature of competition? Application-engineering + service + ROI/sustainability selling vs cost-competitive commodity chemistry (Solenis) and equipment/engineering players (Veolia/Xylem). (Fact.)
• Switching costs? High relative to the small $ of the chemical: installed dispensers, trained service relationship, regulatory/food-safety validation, audit regimes, chain corporate-account lock-in; reinforced by agency dynamics. (Interpretation, the core moat.)

Financial Condition & Balance Sheet

• Assets not on the balance sheet? The ~48,000-person service force, decades of regulatory dossiers/food-safety approvals, and customer relationships are the real (intangible, largely unbooked) franchise value — replication cost vastly exceeds book. (Interpretation.)
• Off-balance-sheet liabilities? Operating leases capitalized; pension liabilities ~$546M; no unusual off-balance-sheet exposure flagged. (Fact.)
• Accounting conservatism? Reasonable; use adjusted EPS for run-rate (GAAP distorted by the 2024 surgical gain +$0.90 and 2020 ChampionX separation loss). SBC small (~$137M). (Fact + Interpretation.)
• CapEx-hungry? Moderate (~7% of sales) and rising with electronics-water/Ovivo; service-segment lines (Pest, Institutional) are asset-lighter. (Fact.)

Capital Allocation & Management

• FCF generation / use / philosophy? ~$1.83B FCF (FY25); used for dividends (~$754M), buybacks (~$784M) and M&A; FY25 capital return ~84% of FCF. Philosophy: grow the algorithm, pay a rising dividend, buy scale/growth (often at full prices), prune non-core. (Fact + Interpretation.)
• Significant acquisitions recently? Yes — Ovivo Electronics ($1.6B, Dec 2025) and pending CoolIT (~$4.75B, 29x EBITDA, AI cooling), debt-funded via $5.0B senior notes. The defining capital-allocation event. (Fact.)
• Buying back shares? Modestly ($784M FY25), largely offsetting SBC/vesting (shares −~2.5% over 2019–25), executed near record multiples — mediocre buyback efficiency. (Fact + Interpretation.)
• Issuing shares to insiders? SBC ~$137M/yr (~0.8% of sales) — modest. (Fact.)
• Compensation policy? CEO Beck $17.4M (FY25), 326x ratio, say-on-pay ~90%. MIP = adjusted EPS + organic sales + margin + FCF; LTIP = organic-ROIC gate + relative-TSR modifier (15.9% target). Above-average alignment, but ROIC metric excludes purchase accounting (doesn’t restrain rich M&A). (Fact + Interpretation.)
• Management motivations? Aligned with EPS/ROIC/TSR; no founding family; Cascade/Gates (12.18%) a patient anchor with a board seat. Insiders net mildly bullish (director $2M open-market buy June 2026). (Fact + Interpretation.)

Valuation & Market Data

• ADR / MLP / K-1? No — standard U.S. C-corp common stock, NYSE-listed, issues a 1099. (Fact.)
• Dividend policy? Dividend Aristocrat: 34 consecutive annual increases, 89 years of paying; ~36% payout, ~1.3% yield, double-digit growth — a dividend-growth story. (Fact.)
• Profitability? Gross 44.5%, op ~18%, net ~13%, ROIC ~13% — high-margin, mid-teens-return. (Fact.)
• Net income vs cash from operations diverging? No — OCF/NI ~1.42x (FY25), clean conversion; FCF ~$1.83B. (Fact.)

Risks & Downside

• What would cause the stock to decline? A multiple de-rate (the dominant lever — from 36x toward the water-peer ~26–30x); a CoolIT disappointment/impairment into ~3x leverage; gross-margin reversal on raw-material re-inflation; a volume stall; share loss in Institutional. (Interpretation.)
• Catastrophic loss risk? Low — IG balance sheet, diversified, FCF-generative; the realistic downside is a ~15–25% drawdown on de-rate, not impairment of the enterprise. (Interpretation.)
• Total loss? Negligible — no solvency risk; even pro-forma ~3x leverage is serviceable on ~$3.9B EBITDA. (Interpretation.)

Recent News & Events

• Business environment changed recently? Yes — (i) the CoolIT acquisition + ~$5B debt issuance (the dominant 2026 event); (ii) renewed commodity inflation (+9% Q1’26, expected offset within a few quarters); (iii) the high-growth engines (High-Tech/data centers, bioprocessing, Digital) inflecting +20%+. (Fact.)
• Significant acquisitions? Ovivo (closed Dec 2025), CoolIT (pending, ~3Q26 close). (Fact.)
• Accounting policy changes? Q1 2025 re-segmentation into four reportable segments (presentation change, not an accounting-policy change). (Fact.)
• Recent changes (markets/facilities/management)? Board refresh (Doukeris, Whalen added; Reich retiring); Beck added President title (April 2026); clean internal supply-chain succession; expansion into AI data-center cooling and semiconductor ultrapure water. (Fact.)

APPENDIX B — Source Appendix

Ecolab Inc. (NYSE: ECL) — Source Appendix

Report date 2026-06-19. Primary sources first. Accessed 2026-06-19 unless noted.

A. Primary — SEC filings (EDGAR, CIK 0000031462)

1. FY2025 Form 10-K, filed 2026-02-23 — Item 1 Business (segments, sales model, competition, R&D); Item 5 (dividends — 34th consecutive annual increase, 89 years paying, $0.73/qtr, $2.68 declared, buyback authorization 5,896,821 shares remaining); Item 7 MD&A (margins, buybacks $784M/$987M/$14M, dividends $754M/$664M/$617M, acquisitions ~$1.64B); segment note (Water $7,679.9M/$1,263.9M; I&S $5,962.0M/$1,357.8M; Pest $1,219.2M/$237.1M; Life Sciences $706.1M/$120.7M); Note 3 special (gains) & charges ($150.3M); Note 4 Acquisitions & Dispositions (Ovivo $1,595.7M PPA — goodwill $1,105.4M, intangibles $618.3M; Global Surgical Solutions divestiture gain $355.9M/$257.7M after-tax). https://www.sec.gov/Archives/edgar/data/31462/000110465926018357/
2. 8-K 2025-03-28 — segment recast confirming Q1’25 re-segmentation (Global Industrial→Global Water; Healthcare folded into Institutional; Life Sciences standalone). https://www.sec.gov/Archives/edgar/data/0000031462/000155837025004009/
3. 8-K 2026-03-20 + Exhibit 99.1 — CoolIT Systems acquisition: ~$4.75B cash from KKR (“Frigeo Holdings”); “29x and 24x estimated next-12-month and 2027 adjusted EBITDA”; ~$550M NTM sales; ~3Q26 close; doubles Global High-Tech opportunity ~$5B→$10B; CEO Beck quote. https://www.sec.gov/Archives/edgar/data/31462/000110465926032446/tm269446d1_ex99-1.htm
4. 8-K 2026-04-15 (Item 1.01) — $4.75B unsecured delayed-draw term loan (Citibank agent), proceeds restricted to financing the CoolIT/Frigeo acquisition. https://www.sec.gov/Archives/edgar/data/31462/000110465926043821/
5. 8-K 2026-05-29 (Item 8.01) — completed $5.0B senior notes: $1.2B 4.600% '29, $0.9B 4.800% '31, $1.5B 5.150% '33, $1.4B 5.350% '36 (term-out of the CoolIT term loan). https://www.sec.gov/Archives/edgar/data/31462/000110465926068276/
6. DEF 14A filed 2026-03-20 (tm2530816-3) — CEO Beck FY25 total comp $17,404,935 (vs $16,390,924 FY24); pay ratio 326x ($53,462 median); say-on-pay ~90%; MIP = adjusted diluted EPS (actual $7.53, 137% payout) + organic sales/margin/FCF; PBRSU = organic ROIC (hard gate, no payout below threshold) + relative-TSR modifier; 2026–2028 organic-ROIC target 15.9% (threshold 11.8%, max 17.8%); “adjusted ROIC excluding purchase-accounting impact and special charges”; Cascade Investment / Gates Foundation Trust 34,396,785 shares = 12.18%; Michael Larson director since 2012; Vanguard 8.21%; BlackRock 7.69%. https://www.sec.gov/Archives/edgar/data/31462/000110465926032777/tm2530816-3_def14a.htm
7. Form 4 corpus — 284 filings (Jan-2024 → Jun-2026): code tally A255/M112/S85/F61/P10/G3. Open-market buys (code P): Michel Doukeris 7,750 sh @ ~$258 ≈ $2.0M (2026-06-11); Benjamin Clark 1,000 sh @ ~$264 ≈ $264K (2026-06-15); David MacLennan recurring 650–1,000-sh quarterly accumulation (2024–2026). Sales overwhelmingly Cascade/Gates programmatic 10b5-1 (still 12.18% holder). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=31462&type=4
8. 8-K Item 5.02 events — Doukeris director (2025-02-20); Duijser resignation (2025-07-18); Whalen director (2025-08-06); Reich non-renewal (2026-02-23).

• (Full 60-month corpus mirrored locally under output/ECL/sources/ with MANIFEST.csv.)

B. Primary — earnings call

9. Q1 2026 earnings call transcript, 2026-04-28 (via ROIC.ai) — adj. diluted EPS +13%; organic sales +4% (price +3%, volume +1%); Global High-Tech & Digital both +20%+; Life Sciences +11% (bioprocessing “more than doubled”); commodity cost +9%, full offset expected “within a few quarters”; FY26 guide adj. diluted EPS +12–15% (ex-CoolIT); CoolIT off to a “very strong start,” Q1 sales “well ahead of the 30%+.”

C. Quantitative data feeds

10. ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/valuation ratios FY2019–2025 and TTM (revenue, margins, ROIC 13.1% FY25 / 8.5% FY22 trough, ROE 16.5%, EV ~$84B, P/E ~36x, EV/EBITDA ~21x, EV/sales ~5.1x); comp multiples for SHW/LIN/ROP/IEX/XYL/VLTO/DHR (TTM 2026-Q1). Third-party aggregated; reconciled to the 10-K.
11. AZI — price history CSV (5-yr OHLCV, EMAs, beta) and valuation-index own-history percentiles (composite 66th, P/E 55th, P/B 65th, P/S 78th; price $269.12, 2026-06-18); news feed (sparse: Wells Fargo EW $275 PT, 2026-06-10).
12. FactorsToday — stock-info (beta 0.59, market cap ~$75.7B, rs figures), leaderboard (y1 +4.5%, y3 +15.7%, y5 +5.9%, y10 +9.6%, lifetime +11.6%; max DD −43.7%; m3 +22.5% ann.), loadings (Market +0.73, Materials +0.38, LowVolatility +0.23, Quality +0.12, Growth −0.16), specific vol 15.1%, related-stocks (AVY, PPG, SHW, NOBL, CGW, min-vol ETFs).

D. Industry & secondary

13. Global industrial water-treatment market size ~$46B (2024) → ~$72–81B (2033–35), ~5% CAGR — Grand View Research; GlobeNewswire (2025-11-11).
14. Water-treatment-chemicals market share (Ecolab #1, Solenis ~20%, Kemira; top-3 >30%) — Reportprime; MarketsandMarkets; Chemical Week (2025-10).
15. Solenis/Diversey (Platinum Equity, >$8B combined) — Platinum Equity release; Chemical Week (2025). Veolia full ownership of Water Technologies & Solutions (May 2025) — industry reports.
16. Data-center liquid-cooling competitive set (Vertiv, Schneider/Motivair, nVent, Boyd, Asetek, Delta) and ECL High-Tech framing — Futurum; SmartWaterMagazine; IndexBox; company materials.
17. Rentokil (RTO) ~21x fwd P/E / ~13–14x EV/EBITDA — WebSearch (stockanalysis.com / Morningstar, Jan 2026).

E. Analytical frameworks

18. Greenwald & Kahn, Competition Demystified — customer-captivity/switching-cost + scale moat taxonomy; market-share-stability & ROIC tests; EPV vs asset value. Chancellor (ed.), Capital Returns (Marathon) — supply-side capital-cycle analysis; the asset-growth anomaly; capital flooding into AI data-center cooling. Applied throughout the Industry, Competitive Position and Capital Allocation sections.

Management commentary is treated as a hypothesis and validated against filings, financials and external evidence throughout.